Mount Yale Investment Advisors LLC Has $373,000 Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Mount Yale Investment Advisors LLC lessened its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 56.7% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,174 shares of the medical equipment provider’s stock after selling 6,775 shares during the period. Mount Yale Investment Advisors LLC’s holdings in Hologic were worth $373,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Wolff Wiese Magana LLC acquired a new stake in Hologic in the third quarter valued at $25,000. General Partner Inc. acquired a new stake in shares of Hologic in the fourth quarter valued at approximately $26,000. First Horizon Advisors Inc. boosted its stake in shares of Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares during the period. Sunbelt Securities Inc. acquired a new position in shares of Hologic during the 2nd quarter worth approximately $37,000. Finally, Cromwell Holdings LLC lifted its holdings in Hologic by 330.2% during the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 416 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the sale, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 1.88% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Leerink Partners dropped their price objective on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. William Blair restated an “outperform” rating on shares of Hologic in a research report on Monday, January 13th. Morgan Stanley decreased their target price on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. JPMorgan Chase & Co. increased their target price on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Finally, UBS Group boosted their price objective on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Seven research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $88.92.

Hologic Stock Down 0.5 %

Shares of NASDAQ:HOLX opened at $71.41 on Thursday. Hologic, Inc. has a 52-week low of $68.61 and a 52-week high of $84.67. The company has a market capitalization of $16.12 billion, a PE ratio of 21.44, a price-to-earnings-growth ratio of 2.43 and a beta of 0.97. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. The company has a fifty day moving average of $73.62 and a 200-day moving average of $78.16.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. During the same period last year, the company earned $0.89 earnings per share. The business’s quarterly revenue was up 4.5% on a year-over-year basis. On average, equities analysts predict that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.